Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon <i>EGFR</i> Mutations: A Comparative Cohort Study in China (AFANDA Study)

Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon <i>EGFR</i> Mutations: A Comparative Cohort Study in China (AFANDA Study)

(1) Background: Afatinib has been approved for patients with non-small cell lung cancer (NSCLC) carrying major uncommon epidermal growth factor receptor gene (<i>EGFR</i>) mutations. Dacomitinib, another second-generation tyrosine kinase inhibitor, has also shown promising potential for...

Full description

Bibliographic Details
Main Authors: Hong-Shuai Li, Shou-Zheng Wang, Hai-Yan Xu, Xiang Yan, Jin-Yao Zhang, Si-Yu Lei, Teng Li, Xue-Zhi Hao, Tao Zhang, Guang-Jian Yang, Li-Qiang Zhou, Peng Liu, Yu-Ying Wang, Xing-Sheng Hu, Pu-Yuan Xing, Yan Wang
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Cancers
Subjects:
non-small cell lung cancer
dacomitinib
afatinib
uncommon EGFR mutations
efficacy
safety
Online Access:https://www.mdpi.com/2072-6694/14/21/5307

Internet

https://www.mdpi.com/2072-6694/14/21/5307

Similar Items